These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 15153938

  • 1. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
    Quist SR, Wang-Gohrke S, Köhler T, Kreienberg R, Runnebaum IB.
    Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
    [Abstract] [Full Text] [Related]

  • 2. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [Abstract] [Full Text] [Related]

  • 3. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL, Lipari P, Dell J, Gurnani M, Hajian G.
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [Abstract] [Full Text] [Related]

  • 4. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE, Runnebaum IB, Karlan BY, Horowitz JA, Shahin M, Buekers T, Petrauskas S, Kreienberg R, Slamon D, Pegram M.
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [Abstract] [Full Text] [Related]

  • 5. Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells.
    Kigawa J, Sato S, Shimada M, Kanamori Y, Itamochi H, Terakawa N.
    Gynecol Oncol; 2002 Feb; 84(2):210-5. PubMed ID: 11812076
    [Abstract] [Full Text] [Related]

  • 6. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J.
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [Abstract] [Full Text] [Related]

  • 7. Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
    Buller RE, Shahin MS, Horowitz JA, Runnebaum IB, Mahavni V, Petrauskas S, Kreienberg R, Karlan B, Slamon D, Pegram M.
    Cancer Gene Ther; 2002 Jul; 9(7):567-72. PubMed ID: 12082456
    [Abstract] [Full Text] [Related]

  • 8. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.
    Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM.
    Gynecol Oncol; 1999 Nov; 75(2):261-6. PubMed ID: 10525383
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A, Di Cristofano C, Zavaglia M, Giusti L, Menicagli M, Cosio S, Naccarato AG, Genazzani AR, Bevilacqua G, Cavazzana AO.
    Anticancer Res; 2006 Nov; 26(1B):687-93. PubMed ID: 16739339
    [Abstract] [Full Text] [Related]

  • 17. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients.
    You L, Yang CT, Jablons DM.
    Cancer Res; 2000 Feb 15; 60(4):1009-13. PubMed ID: 10706117
    [Abstract] [Full Text] [Related]

  • 18. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.
    Mujoo K, Maneval DC, Anderson SC, Gutterman JU.
    Oncogene; 1996 Apr 18; 12(8):1617-23. PubMed ID: 8622881
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer.
    Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK.
    Clin Cancer Res; 2001 Jun 18; 7(6):1765-72. PubMed ID: 11410518
    [Abstract] [Full Text] [Related]

  • 20. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity.
    Gallardo D, Drazan KE, McBride WH.
    Cancer Res; 1996 Nov 01; 56(21):4891-3. PubMed ID: 8895740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.